| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.1M | — | -47.1% |
| SG&A Expense | $4.8M | — | -21.3% |
| Operating Income | -$8.2M | — | +49.9% |
| Net Income | -$7.6M | — | +50.9% |
| EPS (Basic) | -$2.36 | — | -844.0% |
| EPS (Diluted) | -$2.36 | — | -844.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $33.3M | -28.0% | -47.4% |
| Current Assets | $34.7M | -27.3% | -47.9% |
| Total Assets | $36.5M | -41.5% | -57.6% |
| Current Liabilities | $20.1M | -12.9% | +12.8% |
| Total Liabilities | $24.7M | -43.2% | -37.1% |
| Stockholders' Equity | $11.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$13.0M | — | +6.2% |
| Investing Cash Flow | $20K | — | -99.9% |
| -74.8% |